Description
LuciBet 50 MG/200 MG/25 MG (Bictegravir + Emtricitabine + Tenofovir Alafenamide) is a complete, single-tablet antiretroviral regimen (STR) fixed-dose combination containing Bictegravir 50 mg (second-generation integrase strand transfer inhibitor, INSTI), Emtricitabine 200 mg (nucleoside reverse transcriptase inhibitor, NRTI), and Tenofovir Alafenamide 25 mg (nucleotide reverse transcriptase inhibitor, NtRTI), formulated as film-coated tablets supplied in a 30-tablet pot and manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos. Bictegravir is a pharmacokinetic booster-free, second-generation INSTI that inhibits the strand transfer catalytic step of HIV-1 integrase the viral enzyme required to insert HIV-1 proviral DNA into the host cell chromosome with a high genetic barrier to resistance and demonstrated superiority over dolutegravir-based regimens in virologic efficacy in the pivotal Phase 3 Study 1489.
Emtricitabine and Tenofovir Alafenamide (TAF) are complementary reverse transcriptase inhibitors that terminate HIV-1 DNA synthesis at the reverse transcription stage; TAF achieves approximately 90 percent lower systemic plasma tenofovir exposure than tenofovir disoproxil fumarate (TDF) while delivering significantly higher intracellular tenofovir diphosphate concentrations in lymphoid cells the primary mechanism underlying the clinically established superiority of TAF over TDF in bone mineral density and renal function outcomes.
The approved adult dose of LuciBet is 1 tablet once daily with or without food a complete, self-contained HIV regimen requiring no additional antiretroviral co-administration. In the pivotal Phase 3 clinical program, BIC/FTC/TAF achieved HIV-1 RNA below 50 copies/mL in approximately 97 percent of treatment-naive patients at Week 48, with zero treatment-emergent resistance to Bictegravir, Emtricitabine, or Tenofovir Alafenamide observed across all trials. Searching for LuciBet 50 MG/200 MG/25 MG Bictegravir + Emtricitabine + Tenofovir Alafenamide? Mediaid Pharmacy lists LuciBet within its HIV medicines and Lucius Pharmaceuticals medicines portfolios and ships it worldwide.
Basic Product Information of LuciBet 50 MG/200 MG/25 MG (Bictegravir + Emtricitabine + Tenofovir Alafenamide)
| Brand Name | LuciBet 50 MG/200 MG/25 MG (Bictegravir + Emtricitabine + Tenofovir Alafenamide) |
| Product Name | LuciBet |
| Generic Name | Bictegravir + Emtricitabine + Tenofovir Alafenamide INN (fixed-dose combination; also abbreviated B/F/TAF or BIC/FTC/TAF) |
| Drug Class | Bictegravir: Second-Generation Integrase Strand Transfer Inhibitor (INSTI), Booster-Free; Emtricitabine: Nucleoside Reverse Transcriptase Inhibitor (NRTI), Cytidine Analog; Tenofovir Alafenamide: Nucleotide Reverse Transcriptase Inhibitor (NtRTI), Adenosine Monophosphate Prodrug; Complete Single-Tablet Antiretroviral Regimen (STR) for HIV-1 Infection |
| Formulation | Film-Coated Tablet (Oral Fixed-Dose Combination) |
| Available Strength | Bictegravir 50 mg / Emtricitabine 200 mg / Tenofovir Alafenamide 25 mg per tablet |
| Available Pack Size | 30 Tablets per Pot (equivalent to a 1-month supply at the approved adult dose of 1 tablet once daily) |
| Therapeutic Category | HIV Medicines; Antiretroviral Agents; Complete Single-Tablet HIV Regimen; Integrase Strand Transfer Inhibitor (INSTI) + NRTI + NtRTI Combination; Lucius Pharmaceuticals Medicines |
| Approved Indication | HIV-1 Infection: Treatment of HIV-1 infection in adults who are antiretroviral treatment-naive, or adults who are virologically suppressed (HIV-1 RNA below 50 copies/mL) on a stable antiretroviral regimen for at least 3 months with no history of treatment failure and no known substitutions associated with resistance to Bictegravir, Emtricitabine, or Tenofovir Alafenamide. Not for use in patients with HIV-2 infection or prior INSTI resistance. |
| Dosing | Adults: 1 tablet of LuciBet once daily with or without food. LuciBet is a complete antiretroviral regimen no additional antiretroviral agents should be added. Swallow tablets whole. Administer at the same time each day. Not recommended for CrCl below 30 mL/min or severe hepatic impairment (Child-Pugh C). |
| Manufacturer | Lucius Pharmaceuticals (Lao) Co., Ltd., Laos |
| Country of Origin | Laos (Lao People’s Democratic Republic) |
| Originator Reference Brand | Biktarvy (Bictegravir 50 mg / Emtricitabine 200 mg / Tenofovir Alafenamide 25 mg tablets, by Gilead Sciences, Inc., approved by the U.S. FDA on February 7, 2018, for the treatment of HIV-1 infection in adults and pediatric patients). LuciBet contains the same three active pharmaceutical ingredients, Bictegravir, Emtricitabine, and Tenofovir Alafenamide INN, at the same approved fixed-dose strengths (50 mg / 200 mg / 25 mg), manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos and supplied through Mediaid Pharmacy for international procurement. |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Storage Conditions | Store at controlled room temperature (20°C to 25°C); excursions permitted between 15°C and 30°C. Keep in the original container with the lid tightly closed. Protect from moisture. Keep out of the reach of children. |
What Is LuciBet 50 MG/200 MG/25 MG (Bictegravir + Emtricitabine + Tenofovir Alafenamide)?
LuciBet 50 MG/200 MG/25 MG (Bictegravir + Emtricitabine + Tenofovir Alafenamide) is a complete single-tablet antiretroviral regimen (STR) for the treatment of HIV-1 infection, manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos. Each LuciBet tablet contains three distinct antiretroviral agents representing two drug classes: Bictegravir 50 mg a second-generation, pharmacokinetic booster-free integrase strand transfer inhibitor (INSTI) with a high genetic barrier to resistance; Emtricitabine 200 mg a cytidine analog nucleoside reverse transcriptase inhibitor (NRTI); and Tenofovir Alafenamide 25 mg a next-generation nucleotide reverse transcriptase inhibitor (NtRTI) prodrug with a superior bone and renal safety profile compared to the earlier prodrug tenofovir disoproxil fumarate (TDF). The three-component combination covers three independent steps and enzymatic targets in the HIV-1 replication cycle integration, and two complementary stages of reverse transcription providing overlapping antiviral suppression that effectively eliminates HIV-1 replication while maintaining a high barrier to the emergence of drug resistance.
LuciBet represents the Lucius Pharmaceuticals (Lao) formulation of the BIC/FTC/TAF combination the same active ingredients as the originator brand Biktarvy (Gilead Sciences, Inc., U.S. FDA approved February 7, 2018) at the same strengths of 50 mg, 200 mg, and 25 mg per tablet. The LuciBet dosing schedule 1 tablet once daily with or without food represents a complete HIV antiretroviral regimen in a single tablet with no food requirement, no pharmacokinetic booster, no companion agent, and no genotype-specific dose variation, making it the most simplified antiretroviral regimen structure currently recommended by the U.S.
Department of Health and Human Services (DHHS) and the European AIDS Clinical Society (EACS) as a preferred first-line regimen for HIV-1 treatment-naive adults. In the pivotal Phase 3 clinical studies evaluating BIC/FTC/TAF (Studies 1489 and 1490), HIV-1 RNA below 50 copies/mL was achieved in 97.1 percent and 97.3 percent of treatment-naive adults at Week 48, respectively, with no treatment-emergent resistance to Bictegravir, Emtricitabine, or Tenofovir Alafenamide detected in any participant across all trials. LuciBet is supplied as film-coated tablets in a 30-tablet pot a 1-month supply at the approved daily dose and is available globally through Mediaid Pharmacy’s HIV medicines portfolio with worldwide shipping.
Mechanism of Action of LuciBet: Integrase Strand Transfer Inhibition and Dual Reverse Transcriptase Inhibition
LuciBet 50 MG/200 MG/25 MG (Bictegravir + Emtricitabine + Tenofovir Alafenamide) acts through three independently validated antiviral mechanisms that collectively suppress HIV-1 replication at two critical enzymatic steps reverse transcription and chromosomal integration in the HIV-1 life cycle. The combination’s clinical effectiveness and high genetic barrier to resistance arise from the requirement for multiple simultaneous resistance mutations across two distinct viral enzymes (HIV-1 integrase and HIV-1 reverse transcriptase) for meaningful viral breakthrough to occur.
Bictegravir (50 mg) Second-Generation Booster-Free Integrase Strand Transfer Inhibitor (INSTI): Bictegravir inhibits the strand transfer catalytic activity of HIV-1 integrase the viral enzyme responsible for integrating the double-stranded HIV-1 DNA (made by reverse transcriptase) into the host cell’s chromosomal DNA. HIV-1 integrase catalyzes integration in two sequential steps: 3′-processing (cleaving two nucleotides from each 3′ end of the viral DNA) and strand transfer (inserting the processed viral DNA ends into host chromosomal DNA).
Bictegravir selectively inhibits the strand transfer step by binding to the active site of the integrase-viral DNA complex (the pre-integration complex) and chelating the two magnesium divalent cations (Mg²⁺) required for catalysis, preventing the insertion of viral DNA into the host genome and halting productive HIV-1 infection at the integration stage. Bictegravir does not require co-administration of a pharmacokinetic booster (cobicistat or ritonavir) to achieve therapeutic plasma concentrations a critical simplification compared to several earlier INSTIs.
The binding affinity of Bictegravir for the HIV-1 integrase active site, combined with a slow dissociation rate from the integrase-DNA complex, confers a high genetic barrier to resistance: the major resistance-associated substitutions (RASs) that reduce susceptibility to first-generation INSTIs (Q148H/K/R, N155H, Y143C/H/R for raltegravir; R263K for dolutegravir) also reduce susceptibility to Bictegravir only minimally or not at all in phenotypic testing, and no treatment-emergent resistance to Bictegravir was observed in any arm of the Phase 3 pivotal program through Week 96.
Emtricitabine (200 mg) Cytidine Analog Nucleoside Reverse Transcriptase Inhibitor (NRTI): Emtricitabine (FTC) is a fluorinated cytidine analog prodrug. After cellular uptake, FTC is phosphorylated by cellular kinases to its active triphosphate form, FTC-triphosphate (FTC-TP), which has an intracellular half-life of approximately 39 hours. FTC-TP competes with the natural substrate deoxycytidine triphosphate (dCTP) for incorporation into the growing HIV-1 DNA chain by HIV-1 reverse transcriptase (RT). Once incorporated, FTC-TP lacks the 3′-hydroxyl group required for phosphodiester bond formation with the next nucleotide, causing obligate chain termination of HIV-1 reverse transcription. FTC is also active against hepatitis B virus (HBV) reverse transcriptase, making HBV status assessment before initiating LuciBet and HBV flare monitoring after discontinuation in HBV-coinfected patients clinically mandatory.
Tenofovir Alafenamide (25 mg) Next-Generation Adenosine Monophosphate Prodrug NtRTI: Tenofovir Alafenamide (TAF) is a phosphonamidate prodrug of tenofovir, an acyclic nucleotide analog of adenosine monophosphate (AMP). TAF is designed to be stable in plasma (unlike the earlier prodrug TDF, which releases tenofovir extracellularly) and penetrates lymphocytes and other HIV-1 target cells efficiently, where it is hydrolyzed intracellularly by cathepsin A to release tenofovir. Tenofovir is then sequentially phosphorylated to tenofovir diphosphate (TFV-DP) the active form by cellular adenylate kinase and other nucleotide kinases.
TFV-DP achieves approximately 5- to 10-fold higher intracellular concentrations in peripheral blood mononuclear cells (PBMCs) with TAF 25 mg than with TDF 300 mg. Concurrently, plasma tenofovir concentrations with TAF 25 mg are approximately 90 percent lower than with TDF 300 mg directly explaining the significantly lower rates of renal tubular dysfunction (proximal tubulopathy, Fanconi syndrome) and bone mineral density reduction observed with TAF-containing regimens versus TDF-containing regimens in head-to-head clinical trials. TFV-DP competes with deoxyadenosine triphosphate (dATP) for incorporation into HIV-1 DNA by reverse transcriptase; once incorporated, TFV-DP causes obligate chain termination through the same 3′-OH absence mechanism as FTC-TP. TAF also retains potent anti-HBV activity.
LuciBet 50 MG/200 MG/25 MG: Dosing by Patient Population and Clinical Setting
| Patient Population | LuciBet Regimen | Pivotal Week 48 Outcome |
| HIV-1 treatment-naive adults (no prior antiretroviral therapy) | LuciBet 1 tablet (BIC 50 mg + FTC 200 mg + TAF 25 mg) once daily with or without food. No additional antiretroviral agents required. No food restriction. No pharmacokinetic booster. Initiate after confirming no prior INSTI resistance-associated substitutions in patients with detectable resistance testing history. Baseline resistance genotyping recommended per HIV treatment guidelines. | 97.1% HIV-1 RNA <50 copies/mL (Study 1489, vs ABC/DTG/3TC); 97.3% (Study 1490, vs DTG+FTC/TDF) |
| Virologically suppressed adults switching from a stable antiretroviral regimen (HIV-1 RNA <50 copies/mL for ≥3 months) | Switch to LuciBet 1 tablet once daily. Confirm no history of virologic failure, no prior INSTI failure, and no known substitutions conferring resistance to BIC, FTC, or TAF before switching. Discontinue prior antiretroviral regimen simultaneously do not overlap regimens. Switch may be motivated by simplification, tolerability improvement (from TDF to TAF for renal/bone benefit), or regimen consolidation. | 99.3–99.4% maintained HIV-1 RNA <50 copies/mL at Week 48 (Study 1878 switch trials) |
| Adults with mild to moderate renal impairment (CrCl 30 mL/min or above) | LuciBet 1 tablet once daily. No dose adjustment required for CrCl ≥30 mL/min. Monitor renal function periodically throughout treatment. The TAF component of LuciBet provides a significantly improved renal safety profile versus TDF-based regimens, supporting its use in patients with CrCl ≥30 mL/min who would not be suitable candidates for TDF-containing regimens. | No dose adjustment needed; monitor renal parameters |
| Adults with mild to moderate hepatic impairment (Child-Pugh A or B) | LuciBet 1 tablet once daily. No dose adjustment required for Child-Pugh A or B hepatic impairment. In HBV/HIV co-infected patients with hepatic impairment, special caution is required regarding HBV reactivation risk upon LuciBet discontinuation; always consult the HIV and hepatology specialists before any regimen change in this population. | No dose adjustment needed; monitor hepatic function |
| General Dosing Notes | Swallow LuciBet tablets whole with water. Administer once daily at the same time each day with or without food. Do not crush or split the film-coated tablet. If a dose is missed, take it as soon as possible; if the next scheduled dose is within 18 hours, skip the missed dose and resume the regular schedule. Do not double dose. Each pot of LuciBet contains 30 tablets a complete 1-month supply. HIV-1 treatment is lifelong in most patients; consistent daily adherence to the LuciBet once-daily dose is essential to maintain viral suppression and prevent resistance emergence. The treating HIV specialist or infectious disease physician determines LuciBet suitability, reviews the interaction profile with concurrent medications, and establishes the monitoring schedule before initiating treatment. | |
LuciBet 50 MG/200 MG/25 MG: Drug Interactions, Special Populations, and Important Safety Warnings
| Drug Interactions | Bictegravir is metabolized by CYP3A and UGT1A1 and is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). Bictegravir inhibits the renal transporters OCT2 and MATE1. Emtricitabine and Tenofovir Alafenamide are not significantly metabolized by CYP450 enzymes; TAF is a P-gp and BCRP substrate and is metabolized intracellularly by cathepsin A.
Contraindicated co-medications: Rifampin and rifapentine (potent P-gp and CYP3A4/CYP3A5 inducers; reduce Bictegravir AUC approximately 75% with rifampin loss of virologic efficacy of LuciBet; contraindicated); Dofetilide (Bictegravir inhibits renal organic cation transporter OCT2, increasing dofetilide plasma concentrations risk of serious, life-threatening ventricular arrhythmias; contraindicated). Not recommended co-medications: St. John’s Wort (Hypericum perforatum; reduces Bictegravir exposure via P-gp induction; not recommended); Carbamazepine, oxcarbazepine, phenobarbital, phenytoin (reduce Bictegravir exposure via CYP3A/P-gp induction; not recommended may result in loss of virologic response); Rifabutin (reduces Bictegravir AUC approximately 38%; not recommended). Metformin (OCT2/MATE1 interaction): Bictegravir inhibits OCT2 and MATE1, the primary renal transporters responsible for metformin secretion; co-administration increases metformin plasma concentrations and the risk of metformin-associated lactic acidosis, particularly in patients with renal impairment. Reduce the metformin dose before initiating LuciBet or monitor metformin-associated adverse effects closely, especially in patients with CrCl 30–60 mL/min. Polyvalent cation-containing products: Antacids containing aluminum, magnesium, or calcium hydroxide; calcium- or iron-containing supplements; or multivitamins containing zinc or iron: these agents can chelate Bictegravir and reduce its absorption. Separate LuciBet administration from polyvalent cation-containing products by at least 2 hours. Proton pump inhibitors (PPIs) and H2-receptor antagonists: no clinically significant reduction in Bictegravir, Emtricitabine, or TAF absorption no dose separation required, and LuciBet can be co-administered with PPIs or H2RAs without restriction. HBV co-infection requirement: Test all patients for HBV before initiating LuciBet. Both Emtricitabine and Tenofovir Alafenamide are active against HBV; if LuciBet is discontinued in a patient with chronic HBV infection, severe acute exacerbations of HBV have been reported, some resulting in hepatic decompensation or hepatic failure. Monitor hepatic function for at least several months after LuciBet discontinuation in all HBV-coinfected patients. Disclose all medications, herbal supplements, and dietary aids to the treating HIV specialist before initiating LuciBet. |
| Renal Impairment | LuciBet does not require dose adjustment for patients with mild (CrCl 60–89 mL/min) or moderate (CrCl 30–59 mL/min) renal impairment. LuciBet is not recommended for patients with severe renal impairment (estimated CrCl below 30 mL/min) or end-stage renal disease (ESRD) requiring hemodialysis, dialysis, or other forms of renal replacement therapy, because adequate pharmacokinetic and safety data are not available for emtricitabine and tenofovir alafenamide in these populations and drug accumulation is expected. The Tenofovir Alafenamide (TAF) component of LuciBet provides a substantially improved renal safety profile compared to tenofovir disoproxil fumarate (TDF): Phase 3 head-to-head trials comparing FTC/TAF with FTC/TDF demonstrated significantly lower rates of serum creatinine increases, significantly smaller declines in eGFR, and significantly lower rates of markers of proximal tubular dysfunction (urine protein-to-creatinine ratio, retinol-binding protein) with TAF across 48 and 96 weeks, supporting the use of LuciBet over TDF-containing regimens in HIV-1 patients with pre-existing renal concerns. Renal function must be assessed before initiating LuciBet and monitored periodically throughout the treatment course, particularly in patients with pre-existing renal disease, diabetes, hypertension, or concurrent nephrotoxic medications. |
| Hepatic Impairment | No dose adjustment of LuciBet is required for patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment based on pharmacokinetic studies of the individual components demonstrating that Bictegravir, Emtricitabine, and Tenofovir Alafenamide exposure are not substantially altered at these degrees of hepatic impairment. LuciBet is not recommended for patients with severe hepatic impairment (Child-Pugh C) due to insufficient pharmacokinetic and safety data in this population. In HBV/HIV-1 co-infected patients with any degree of hepatic impairment, the risk of HBV flare upon LuciBet discontinuation is particularly high; hepatic function must be monitored closely throughout treatment and for several months after any discontinuation. For all HIV-1 patients with hepatic impairment, hepatic function parameters should be monitored at baseline and throughout the LuciBet treatment course. |
| Immune Reconstitution Inflammatory Syndrome (IRIS) | Immune reconstitution inflammatory syndrome (IRIS) has been reported in HIV-1 patients initiating or intensifying antiretroviral therapy, including BIC/FTC/TAF-containing regimens. IRIS occurs when the reconstituting immune system generates an inflammatory response to previously subclinical or treated opportunistic infections (e.g., Mycobacterium avium complex, cytomegalovirus, Pneumocystis jirovecii pneumonia, tuberculosis) or autoimmune disorders (e.g., Graves’ disease, polymyositis, Guillain-Barré syndrome) in the weeks to months following initiation of effective ART. Most cases of IRIS can be managed without interruption of antiretroviral therapy. The treating HIV specialist must evaluate and manage any clinical deterioration occurring in the first weeks to months after LuciBet initiation in the context of possible IRIS. |
| Pregnancy and Lactation | Based on current evidence and antiretroviral pregnancy registry data, Bictegravir, Emtricitabine, and Tenofovir Alafenamide have not demonstrated increased rates of birth defects at clinically relevant exposures. DHHS Perinatal Guidelines acknowledge limited human data for BIC in pregnancy; however, BIC/FTC/TAF is listed as an alternative antiretroviral regimen for pregnant people living with HIV when preferred regimens are not appropriate, given its strong virologic efficacy, high barrier to resistance, and once-daily tablet simplicity. Emtricitabine and Tenofovir Alafenamide pharmacokinetics may be altered in pregnancy; monitoring of viral load is essential throughout pregnancy on any antiretroviral regimen. HIV-1 can be transmitted through breast milk; the WHO and CDC both recommend that HIV-positive individuals not breastfeed when replacement feeding is safe, feasible, affordable, sustainable, and acceptable. Consult the treating HIV specialist and obstetrician before initiating, continuing, or modifying LuciBet during pregnancy or the periconception period. |
Who Should Use LuciBet 50 MG/200 MG/25 MG (Bictegravir + Emtricitabine + Tenofovir Alafenamide)?
LuciBet 50 MG/200 MG/25 MG (Bictegravir + Emtricitabine + Tenofovir Alafenamide) is indicated for adults with HIV-1 infection who are either antiretroviral treatment-naive or who are virologically suppressed on a stable regimen and meet defined switching criteria. HIV-1 infection affects approximately 39.9 million people globally (UNAIDS, 2023) and requires lifelong antiretroviral therapy (ART) to maintain viral suppression, prevent immune deterioration, and reduce the risk of onward HIV transmission. BIC/FTC/TAF is listed as a preferred first-line regimen by the DHHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV and by the European AIDS Clinical Society (EACS) Guidelines due to its high virologic efficacy, zero treatment-emergent resistance in clinical trials, excellent tolerability profile, and single-tablet once-daily convenience.
Antiretroviral treatment-naive HIV-1 patients are the primary LuciBet target population. Study 1489 demonstrated that BIC/FTC/TAF was statistically superior to dolutegravir/abacavir/lamivudine (ABC/DTG/3TC) at Week 48 (97.1% vs 94.6% viral suppression), with the superiority driven in part by fewer discontinuations due to adverse reactions with BIC/FTC/TAF. Study 1490 confirmed non-inferiority of BIC/FTC/TAF versus dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (DTG + FTC/TDF) at Week 48 (97.3% vs 90.5%), with BIC/FTC/TAF demonstrating superior bone and renal laboratory outcomes attributable to the TAF component.
Virologically suppressed adults switching from a prior stable regimen represent the second major LuciBet indication: the Phase 3 Study 1878 switching program confirmed that virologically suppressed adults switching to BIC/FTC/TAF from a variety of prior regimens (including dolutegravir-based, non-nucleoside reverse transcriptase inhibitor-based, and protease inhibitor-based regimens) maintained viral suppression in 99.3 to 99.4 percent of participants at Week 48 supporting LuciBet as a safe and virologically reliable simplification or tolerability-improvement switch for a broad population of established HIV-1 patients.
HIV-1 patients with pre-existing renal or bone concerns are well-served by LuciBet specifically because of the TAF component’s documented superiority over TDF in renal function and bone mineral density outcomes: across Phase 3 trials, TAF-containing regimens produced significantly smaller reductions in hip and spine bone mineral density and significantly lower rates of renal tubular markers of proximal tubular dysfunction compared to TDF-containing comparators through Week 96. Patients who are NOT appropriate for LuciBet include: those with known INSTI resistance-associated substitutions (particularly Q148H/K/R, G140A/S, or combinations of INSTI RASs); those with known M184V/I mutation conferring high-level FTC resistance; those with severe renal impairment (CrCl below 30 mL/min) or ESRD; those with severe hepatic impairment (Child-Pugh C); those receiving rifampin, rifapentine, or dofetilide; and those with a history of prior INSTI treatment failure.
HIV treatment centers and procurement teams sourcing LuciBet for their patient population can explore the complete HIV medicines collection and the full Lucius Pharmaceuticals medicines portfolio at Mediaid Pharmacy before requesting a consolidated supply quotation.
Global Supplier: Mediaid Pharmacy Worldwide Shipping for LuciBet 50 MG/200 MG/25 MG (Bictegravir + Emtricitabine + Tenofovir Alafenamide)
Mediaid Pharmacy is a Dhaka-based specialty antiviral medicines supplier with worldwide shipping capability serving patients, HIV treatment centers, infectious disease clinics, hospitals, NGO treatment programs, and international healthcare providers across all regions. LuciBet 50 MG/200 MG/25 MG (Bictegravir + Emtricitabine + Tenofovir Alafenamide), manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos, is supplied as film-coated tablets in a 30-tablet pot with pricing quotations, stock availability confirmation, full product documentation, certificate of analysis, and end-to-end international delivery tracking for every order.
The 30-tablet pot of LuciBet provides a standard 1-month supply at the approved once-daily dose, matching the most common monthly HIV prescription and pharmacy dispensing cycle simplifying patient refill schedules, clinic dispensing planning, and program procurement calendars for HIV treatment programs operating on standard 1-month or 3-month antiretroviral ordering cycles. For patients on lifelong HIV-1 therapy with LuciBet, a 3-month supply requires 3 pots (90 tablets), supporting quarterly procurement scheduling for patient self-supply and program bulk purchasing.
Mediaid Pharmacy provides consolidated procurement pricing and supply continuity assurance for volume orders. Individual HIV patients, infectious disease physicians and HIV specialists managing chronic HIV-1 caseloads, hospital formulary and procurement departments, NGO treatment program procurement coordinators, and international distributors can contact Mediaid Pharmacy through WhatsApp, phone, or WeChat for all inquiries regarding LuciBet 50 MG/200 MG/25 MG Bictegravir + Emtricitabine + Tenofovir Alafenamide stock availability, current pricing, and international delivery timelines to specific destination countries.
Procurement teams co-sourcing LuciBet with other HIV antiretroviral, opportunistic infection prophylaxis, or Lucius Pharmaceuticals specialty medicines can browse the complete HIV medicines collection and the Lucius Pharmaceuticals medicines portfolio at Mediaid Pharmacy before requesting a combined quotation.
Why Choose LuciBet 50 MG/200 MG/25 MG (Bictegravir + Emtricitabine + Tenofovir Alafenamide) from Mediaid Pharmacy?
LuciBet 50 MG/200 MG/25 MG (Bictegravir + Emtricitabine + Tenofovir Alafenamide) gives HIV specialists, infectious disease physicians, treatment program coordinators, and HIV-1 patients access to the most virologically effective, resistance-resilient, and tolerability-optimized single-tablet antiretroviral regimen currently available in guidelines the BIC/FTC/TAF combination manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos and available globally through Mediaid Pharmacy. The three clinical advantages that distinguish LuciBet from all prior complete single-tablet HIV regimens are zero treatment-emergent resistance across Phase 3 trials, superior virologic efficacy demonstrated against dolutegravir-based comparators, and the superior bone and renal safety profile of the TAF component versus TDF.
Zero treatment-emergent resistance to any component through Week 96 of both pivotal Phase 3 trials (Studies 1489 and 1490) and through all switch studies is the defining clinical attribute of BIC/FTC/TAF and reflects Bictegravir’s exceptionally high genetic barrier to resistance the highest of any approved INSTI combined with the established resistance barrier of the FTC/TAF backbone. In clinical practice, zero emergent resistance through nearly two years of observation across thousands of patients confirms that patients adherent to LuciBet’s once-daily dose can expect durable viral suppression without accumulating drug resistance mutations that would compromise future treatment options.
The pharmacokinetic booster-free design of Bictegravir eliminates the drug interaction complexity introduced by cobicistat or ritonavir both potent CYP3A4 inhibitors that accompanies many alternative INSTI-based regimens; this simplifies co-prescription of LuciBet with anticoagulants, antifungals, statins, immunosuppressants, and other medications managed by CYP3A4. The Tenofovir Alafenamide (TAF) component of LuciBet delivers clinically meaningful improvements in bone mineral density and renal function biomarkers compared to TDF-containing regimens through Week 96 a critical long-term tolerability advantage for HIV-1 patients who require lifelong antiretroviral therapy and face cumulative TDF-associated bone and renal toxicity over decades of treatment.
The 30-tablet-per-pot pack format of LuciBet provides a complete 1-month supply at the once-daily dose, directly matching standard monthly pharmacy dispensing cycles and HIV clinic prescription patterns globally. LuciBet is manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos and is available through Mediaid Pharmacy with full product documentation, specialist supply coordination, and worldwide shipping. To source additional Lucius Pharmaceuticals antiretroviral medicines or to review the complete range of HIV treatment options available at Mediaid Pharmacy, visit the Lucius Pharmaceuticals medicines section and the HIV medicines portfolio, and contact the Mediaid Pharmacy team for a personalized quotation.
Frequently Asked Questions About LuciBet 50 MG/200 MG/25 MG (Bictegravir + Emtricitabine + Tenofovir Alafenamide)
What is LuciBet 50 MG/200 MG/25 MG (Bictegravir + Emtricitabine + Tenofovir Alafenamide) used for?
LuciBet 50 MG/200 MG/25 MG (Bictegravir + Emtricitabine + Tenofovir Alafenamide) is a complete single-tablet antiretroviral regimen (STR) used for the treatment of HIV-1 infection in adults who are antiretroviral treatment-naive, or adults who are virologically suppressed (HIV-1 RNA below 50 copies/mL) on a stable antiretroviral regimen for at least 3 months with no history of treatment failure and no known resistance to any component of LuciBet. Bictegravir (50 mg) is a second-generation, booster-free integrase strand transfer inhibitor (INSTI) that prevents integration of HIV-1 proviral DNA into the host cell genome. Emtricitabine (200 mg) and Tenofovir Alafenamide (25 mg) are nucleoside and nucleotide reverse transcriptase inhibitors that terminate HIV-1 DNA synthesis during reverse transcription. In Phase 3 clinical trials, BIC/FTC/TAF achieved HIV-1 RNA below 50 copies/mL in 97.1 to 97.3 percent of treatment-naive adults at Week 48, with zero treatment-emergent resistance to any component. LuciBet is manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos and is available through Mediaid Pharmacy with worldwide shipping to patients, HIV clinics, hospitals, and healthcare providers globally.
What is the generic name of LuciBet?
The generic name of LuciBet is Bictegravir, Emtricitabine, and Tenofovir Alafenamide (International Nonproprietary Names, INN). LuciBet is the brand name registered by Lucius Pharmaceuticals (Lao) Co., Ltd. for the Bictegravir 50 mg, Emtricitabine 200 mg, and Tenofovir Alafenamide 25 mg fixed-dose combination manufactured in Laos. LuciBet is supplied as film-coated tablets in a 30-tablet pot, corresponding to a 1-month supply at the approved adult dose of 1 tablet once daily. The originator reference brand is Biktarvy (Gilead Sciences, Inc.), approved by the U.S. FDA on February 7, 2018, for the treatment of HIV-1 infection in adults and pediatric patients. For the complete range of Lucius Pharmaceuticals medicines available at Mediaid Pharmacy, explore the Lucius pharma product collection.
What is the dose of LuciBet (Bictegravir + Emtricitabine + Tenofovir Alafenamide)?
The approved adult dose of LuciBet (Bictegravir + Emtricitabine + Tenofovir Alafenamide) is 1 tablet (Bictegravir 50 mg + Emtricitabine 200 mg + Tenofovir Alafenamide 25 mg) once daily with or without food. LuciBet is a complete antiretroviral regimen no additional HIV antiretroviral agents are required or recommended alongside LuciBet. Swallow the tablet whole at the same time each day. The 30-tablet pot of LuciBet provides a complete 1-month supply. LuciBet is not recommended for patients with estimated creatinine clearance below 30 mL/min (severe renal impairment or ESRD) or severe hepatic impairment (Child-Pugh C). No dose adjustment is required for mild to moderate renal impairment (CrCl ≥30 mL/min) or mild to moderate hepatic impairment. Always confirm suitability with the treating HIV specialist before initiating LuciBet.
What are the side effects of LuciBet 50 MG/200 MG/25 MG?
The most commonly reported adverse reactions of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Phase 3 clinical trials include diarrhea (14%), nausea (12%), headache (7%), fatigue, and abnormal dreams. Most adverse events were mild to moderate. Serious warnings include: severe acute exacerbation of hepatitis B in HBV/HIV-1 co-infected patients upon discontinuation of emtricitabine or tenofovir alafenamide; lactic acidosis and severe hepatomegaly with steatosis (NRTI class effect, rare); new-onset or worsening renal impairment; immune reconstitution inflammatory syndrome (IRIS); and decreases in bone mineral density (BMD). The TAF component of LuciBet provides a significantly better bone and renal tolerability profile than TDF-based regimens, with substantially smaller BMD reductions and lower rates of renal function biomarker changes across 48 and 96 weeks in Phase 3 trials. All patients must be screened for HBV before initiating LuciBet. Consult the treating HIV specialist for the complete safety profile. For the full range of HIV treatment medicines at Mediaid Pharmacy, explore the complete HIV medicines collection.
Can LuciBet (Bictegravir + Emtricitabine + Tenofovir Alafenamide) be used in patients with renal impairment?
LuciBet (Bictegravir + Emtricitabine + Tenofovir Alafenamide) does not require dose adjustment for patients with mild (CrCl 60–89 mL/min) or moderate (CrCl 30–59 mL/min) renal impairment. LuciBet is not recommended for patients with severe renal impairment (CrCl below 30 mL/min) or end-stage renal disease (ESRD) due to insufficient pharmacokinetic data and the potential for drug accumulation. The Tenofovir Alafenamide (TAF) component of LuciBet provides a substantially superior renal safety profile compared to tenofovir disoproxil fumarate (TDF), with approximately 90 percent lower plasma tenofovir concentrations and significantly lower rates of renal tubular dysfunction biomarkers in Phase 3 head-to-head trials. Renal function must be assessed at baseline and monitored periodically throughout treatment. For additional HIV antiretroviral treatment options available through Mediaid Pharmacy, explore the HIV medicines portfolio.
What drugs interact with LuciBet 50 MG/200 MG/25 MG (Bictegravir + Emtricitabine + Tenofovir Alafenamide)?
Contraindicated co-medications with LuciBet include rifampin and rifapentine (reduce Bictegravir AUC approximately 75% via potent P-gp/CYP3A induction loss of virologic efficacy) and dofetilide (Bictegravir inhibits OCT2, increasing dofetilide plasma concentrations risk of serious/fatal ventricular arrhythmias). Not recommended: St. John’s Wort; carbamazepine, oxcarbazepine, phenobarbital, phenytoin (reduce Bictegravir exposure); rifabutin (reduces Bictegravir AUC approximately 38%). Bictegravir inhibits OCT2 and MATE1, increasing metformin concentrations reduce metformin dose or monitor closely. Antacids or polyvalent cation-containing supplements: separate from LuciBet by at least 2 hours. Proton pump inhibitors and H2-receptor antagonists: no clinically significant interaction no dose separation required. All medications, supplements, and herbal products must be disclosed to the treating HIV specialist before initiating LuciBet. For additional Lucius Pharmaceuticals antiretroviral products, visit the Lucius Pharmaceuticals medicines collection.
Can I order LuciBet 50 MG/200 MG/25 MG (Bictegravir + Emtricitabine + Tenofovir Alafenamide) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies LuciBet 50 MG/200 MG/25 MG (Bictegravir + Emtricitabine + Tenofovir Alafenamide) by Lucius Pharmaceuticals (Lao) Co., Ltd. to patients, HIV treatment centers, infectious disease clinics, cancer hospitals, NGO treatment programs, and healthcare providers globally. Contact Mediaid Pharmacy via WhatsApp, phone, or WeChat at +8801773428128, or email info@mediaidpharmacy.com for pricing, current stock availability, and international delivery details for your country.
Order LuciBet 50 MG/200 MG/25 MG (Bictegravir + Emtricitabine + Tenofovir Alafenamide) with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com
Reviews
There are no reviews yet.